Skip to content

Fremanezumab

Ajovy (fremanezumab) is an antibody pharmaceutical. Fremanezumab was first approved as Ajovy on 2018-09-14. It has been approved in Europe to treat migraine disorders. The pharmaceutical is active against calcitonin; calcitonin gene-related peptide 1.
Trade Name Ajovy
Common Name Fremanezumab
Indication migraine disorders
Drug Class Monoclonal antibodies: humanized, neural indications
Fremanezumab
Get full access now